Skip to content


Emgenex Blogs

Navigating UHC's New Z-Code Requirements for Molecular Testing

September 02, 2023

United Healthcare (UHC) has recently updated its reimbursement policy, creating an additional layer of complexity for molecular testing labs. Initially, UHC had set a compliance deadline of August 1, 2023, for labs to include Diagnostic Exchange (DEX) Z-Code identifiers on claims for molecular diagnostic tests. However, the deadline has been extended to October 1, 2023.

This change is impactful, especially for labs that are not part of a Medicare Administrative Contractor (MAC) that participated in the Molecular Diagnostic Services (MolDX) Program. Until this update, such labs did not face many of the challenges encountered by their counterparts who were part of MolDX. Now, these labs are also mandated to go through the cumbersome process of registering for Z-Codes to get reimbursed for molecular tests like Pharmacogenetics, Urinary Tract Infections (UTI), Respiratory Pathogen Panels (RPP), and more.

Decoding the DEX Z-Code

The DEX Z-Code is a unique five-character alpha-numeric identifier that accompanies certain molecular diagnostic tests. When added to a claim alongside the CPT/HCPCS code, the Z-Code provides increased clarity for both payers and providers about which test is being ordered, performed, and billed. This eliminates ambiguity and ensures accurate billing and reimbursement.

How to Prepare Your Lab

If your lab has not yet registered with the MolDX program, now is the time to do so. The registration process involves three key steps:

  • Register with the MolDX program. 
  • Register the molecular diagnostic tests you offer.
  • Submit a Technical Assessment.

The entire process takes approximately 60 to 120 days to complete, so it's crucial to begin as soon as possible.

Why it Matters?

There are several benefits to registering with MolDX and receiving Z-Codes for your tests. Primarily, it enables labs to establish fixed pricing, creating a consistent and transparent pricing model. Although reimbursement may sometimes be lower, the predictability far outweighs the disadvantages. Further, it reduces denials, much like a preauthorization process would, facilitating a smoother path for your billing team to get reimbursements.

Early Denials: A Word of Caution

One of Emgenex’s lab billing managers reported experiencing denials from UHC for molecular testing as early as August, despite the extension of the compliance deadline to October 1. Our billing team, which works with both labs that are and aren’t part of MACs participating in the MolDX program, emphasizes the importance of staying ahead of these requirements to prevent any disruptions in reimbursements.

In summary, labs, whether part of the MolDX program or not, will need to adapt to these new UHC requirements swiftly. The key to smooth navigation through this change lies in early registration and diligent preparation. If your lab hasn’t started the process yet, now is the time to act.

How Emgenex Can Help

For labs grappling with these new requirements, managing the intricacies of billing can be a daunting task. That's where Emgenex comes in. We specialize in third-party billing, with a specific focus on molecular labs. Our experienced lab billing team is well-versed in the challenges presented by these new UHC requirements. We work with both labs that are and aren't part of MACs participating in the MolDX program, offering tailored solutions that help you meet these new standards efficiently.

Our goal is to mitigate the administrative burden, allowing your lab to focus on what it does best: providing top-notch diagnostic services. From guiding you through the MolDX registration process to ensuring that all tests have the appropriate Z-Codes for optimized reimbursements, Emgenex is your reliable partner in navigating this complex landscape.

Don't let the new billing requirements slow down your operations. Contact Emgenex today to learn how we can streamline your billing process and help you adapt to the evolving healthcare landscape.